Proxima (formerly VantAI) closed an oversubscribed $80 million seed round led by DCVC and backed by Roivant and others to develop AI‑driven proximity‑modulating drugs that target protein interactions. CEO Zachary Carpenter said the firm will combine proteome‑scale structural data with frontier AI to design proximity‑based medicines for oncology and immunology. The financing supports preclinical pipeline expansion and partnerships with biotech and pharma for target validation.